Market Overview

UPDATE: Cantor Fitzgerald Reiterates Buy Rating, Raises PT on CVS Caremark Corporation

Related CVS
Will Rite Aid (RAD) Miss Estimates this Earnings Season?
Benzinga's Top Upgrades
Home Depot Investigates Potential Hacking, CVS Says Farewell to Tobacco Products (Fox Business)

In a report published Friday, Cantor Fitzgerald reiterated its Buy rating on CVS Caremark Corporation (NYSE: CVS), and raised its price target from $55.00 to $57.00.

Cantor Fitzgerald noted, “Despite some concerns over what CVS could possibly do for an encore following some exceptional tailwinds in 2012, the combination of a major dividend increase and very strong (above consensus) EPS guidance set the tone for a very upbeat analyst meeting. We liked what we heard in the management presentations and have greater conviction in our 2013 earnings outlook. We reiterate our BUY rating with a revised price target is $57 (from $55).”

CVS Caremark Corporation closed on Thursday at $48.50.

Latest Ratings for CVS

DateFirmActionFromTo
Sep 2014Cowen & CompanyUpgradesMarket PerformOutperform
Aug 2014BarclaysMaintainsOverweight
Aug 2014JP MorganMaintainsOverweight

View More Analyst Ratings for CVS
View the Latest Analyst Ratings

Posted-In: Cantor FitzgeraldAnalyst Color Price Target Analyst Ratings

 

Related Articles (CVS)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters